Description: Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes, which include broad therapeutic applications, predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases, cancer and autoimmune diseases based on three modalities - cellular shielding, potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU), RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.
Home Page: www.rubiustx.com
RUBY Technical Analysis
399 Binney Street
Cambridge,
MA
02139
United States
Phone:
617 679 9600
Officers
| Name | Title |
|---|---|
| Ms. Dannielle Appelhans | CEO & Pres |
| Mr. Jose I. Carmona M.B.A. | Principal Accounting Officer & Treasurer |
| Dr. Laurence A. Turka M.D. | Chief Scientific Officer and Head of Research & Translational Medicine |
| Ms. Marissa Hanify | Director of Corp. Communications |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4199 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2018-07-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |